Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

Investigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in association with maintenance therapy with atezolizumab.

Trial Details

NCT ID
NCT06771518
Phase
PHASE2
Sponsor
Regina Elena Cancer Institute
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Thoracic radiotherapy
  • Atezolizumab 1200 mg e.v. q21
Locations (sample)
  • Rome, Rome, Italy|41.89193,12.51133

Key Eligibility Criteria

  • Histological diagnosis of lung microcytoma;
  • Age ≥18 years;
  • Performance status according to ECOG 0-2;
  • Extended disease at the time of first line oncological treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →